The Estée Lauder Companies Announces Brand Leadership Promotions
1.7.2021 15:30:00 EEST | Business Wire | Press release
The Estée Lauder Companies (NYSE:EL) announced today the promotions of two brand leaders – Michelle Freyre has been promoted to Global Brand President, Clinique, and Glenn Evans has been promoted to Global Brand President, Smashbox and GLAMGLOW. The promotions are effective July 1, 2021, and both leaders will continue to report directly to John Demsey, Executive Group President, The Estée Lauder Companies (ELC).
“Michelle and Glenn are both incredibly dynamic leaders who have beautifully steered their respective brands through the challenges of the past year,” said John Demsey. “I am particularly proud of how effectively they have balanced the needs of the business while being truly thoughtful and empathetic leaders to their brand teams. Their promotions are both very well-deserved.”
Michelle Freyre Has Been Promoted to Global Brand President, Clinique
A dynamic leader with deep experience leading a variety of beauty brands across categories and channels, Michelle’s promotion to Global Brand President, Clinique, recognizes her outstanding and visionary leadership in returning Clinique to global growth. She was appointed Senior Vice President/Global General Manager, Clinique in June 2020, and since then has made a significant impact on Clinique’s brand positioning, driving double digit growth for hero products, as well as redefining the innovation strategy behind Clinique’s hero franchises. She has also driven Clinique’s acceleration in Online to be the #1 ELC brand in North America in that channel, while delivering the Clinique High-Touch experience at scale globally. Her inspirational leadership, deep expertise in beauty and skin care, together with her strong passion for connecting with global consumers, makes her uniquely suited to continue to lead Clinique in its next chapter of growth.
Michelle joined ELC from Johnson & Johnson in 2020, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of Beauty brands at the time, and led the successful performance and growth of many brands. Prior to that, she served as the General Manager of Neutrogena at J&J, and as the leader of the company’s Los Angeles campus.
Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity. She has received several industry awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.”Michelle is the Executive Sponsor of Hispanic Connections (HiC) ERG and is actively mentoring diverse talent across ELC.
Glenn Evans Has Been Promoted to Global Brand President, Smashbox and GLAMGLOW
With more than 30 years of strategic, operational and brand-building experience, Glenn is an exceptional, values-driven brand leader with an impressive track record of delivering consistent results. As Senior Vice President/Global General Manager, Smashbox and GLAMGLOW, Glenn has successfully led both brands, capturing operational and supply chain synergies between them, optimizing their global brand and regional go-to-market structures and improving A&P effectiveness.
As Global Brand President, Glenn will continue to lead Smashbox and GLAMGLOW into their next phases of sustainable growth, focusing on product innovations with a consumer-led, online-centric, digital-first approach, as well as continuous transformation to evolve ahead of the changing retail landscape. A dynamic and energetic leader, Glenn will also continue to leverage his passion for developing top talent across both brand teams.
Since being named Senior Vice President and General Manager, Smashbox, in 2019, Glenn has led the brand’s repositioning strategy to drive appeal with both new and loyal consumers while staying true to the brand’s core studio heritage. Under his leadership, the brand reinforced its number one ranking in U.S. prestige Face Primers, achieved top rankings in prestige Face Primers in key global markets, and attracted new consumers with the success of Smashbox Halo All-in-One Tinted Moisturizer.
Before his role at Smashbox, Glenn was Senior Vice President, Leading Beauty Forward, where he led the successful global implementation of Leading Beauty Forward and OneSource, which have helped to fuel the company’s multiple engines of growth strategy. Prior to that role, Glenn was SVP, Global Supply Chain, during which time he established and led the Global Supply Chain Center of Excellence for six years, and played a leadership role in integrating and enhancing best-in-class capabilities across the organization.
Since 2018, Glenn has served as an Executive Sponsor of wELCome, ELC’s Employee Resource Group for LGBTQIA+ employees. He continues to act as a passionate advocate for Inclusion & Diversity across the Company. Glenn recently announced the creation of the West Coast chapter of wELCcome and he also sponsors the Smashbox & GLAMGLOW Multi-Ethnic Advisory Board, an employee-led group within the brands that aims to ensure diverse voices are amplified during key moments of decision-making.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005234/en/
Contact information
Investor Relations:
Rainey Mancini
(212) 284-3049
rmancini@estee.com
Media Relations:
Jill Marvin
(212) 572-4438
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 10:00:00 EEST | Press release
Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use cases demonstrating how AI and advanced automation are helping operators address increasing network complexity, strengthen fraud prevention, improve service assurance, and drive operational efficiency. A central theme across
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
